GENERAL
Novo Nordisk Faces Headwinds Amid GLP-1 Drug Frenzy
Novo Nordisk, the maker of Ozempic and Wegovy, faces a challenging market despite the surging popularity of GLP-1 drugs. The company is contending with increased competition, regulatory scrutiny from the FDA, and a significant stock downturn, even as its drugs continue to exert a profound cultural influence and unlock new therapeutic possibilities.